Dissertation > Excellent graduate degree dissertation topics show

A Basal and Clinical Reseach Ofω-3 Polyunsaturated Fatty Acids to Seal Non-alcoholic Fatty Liver Disease

Author: KongXiaoLing
Tutor: JiangChunMeng
School: Dalian Medical University
Course: Internal Medicine
Keywords: non-alcoholic liver disease seal oilω-3 polyunsattlrated fatty acids Adiponectin liver/spleen CT attenuation ratio PPAR-α
CLC: R575.5
Type: Master's thesis
Year: 2011
Downloads: 8
Quote: 0
Read: Download Dissertation

Abstract


Part one:Preventive Effects ofω-3 Polyunsaturated Fatty Acids from seal oil on Mice with Nonalcoholic Fatty LiverObjectives:ω-3 Polyun-saturated Fatty Acids can adjust lipid metabolism. Fatty liver is one pathology appearance of metabolism syndrome.This study aims to investigateω-3 Polyun saturated Fatty Acids to prevent non-alcoholic fatty liver desease.Methods: After 72hours exposing in the SPF condition, 30 male C57BL mice were divided into three groups randomly with 10 in each group: therapy group, model group and the normal group. The normal group fed with common diet, the model group fed with the high fat diet (Liber- Decarli liquid to make nonalcoholic liver disease, which containing 71%fat,18% protein,11% carbohydrate. The therapy group fed with the high-fat diet and seal oil 0.3ml daily. After 6 weeks, all rats were sacrificed , the blood sample and liver tissue were reserved for test. TG, TC in liver tissue and serum were tested by biochemistry method respectively. Heptic cytochrome P4502E1 (CYP2E1), peroxisome proliferator activatied receptor-α(PPAR-α) and adiponectin were detected by immunohistochemistry. The pathology of liver was observed by HE stain and sudanⅢstain .Results:1. The level of steatosis: normal group hepatocyte not seen fatty degeneration; model group hepatocyte generally occurred steatesis, which was covered with fat vacuole; steatosis was remarkably slighter in the treatment group than in model group.2. Biochemical indicator compare: serum TG and TC level of model group (1.38±0.40、4.79±0.71 respectively) were increased significantly compared with normal group(0.55±0.12,2.34±0.44)(P<0.01 respectively). Compared with model group, the treatment group (0.5±0.12、2.75±0.47)were decreased markedly(P<0.05). Liver tissue TG and TC: compared with normal group( 70.63±19.67, 54.27±33.55), the level of model group(260.19±90.78、123.7±32.15) increased significantly(P<0.01 respectively); treatment group (103.58±33.28、52.17±20.24) compared with model group were decreased markedly(P<0.05 respectively).3.Cytokine compare:(1) Adiponectin(mmol/l): model group (7.27±3.45) were decreased significantly compared with normal group (21.68±2.3) (P<0.01). Compared with model group, the treatment group (12.14±0.83) were increased markedly. (2) CYP2E1: compared with model group, the treatment group were decreased markedly(P<0.05). PPAR-α: Compared with model group, the treatment group were increased significantly(P<0.05).Part two:A trial ofω-3 Polyunsaturated Fatty Acids in treatment of patients with non-alcoholic fatty liver diseaseObjectives: This study aims to ascertain the effect and safety ofω3-PUFA on patients with Non-alcoholic liver desease.Methods: It used random, double-blind, compare method to divide into two groups with 20 in each group: therapy group, control group. They were to receive eitherω-3 polyunsaturated fatty acid capsule or placebo 4.0g daily for 6 months. Serum biochemical(TC, TG, HDL, LDL, ALT, AST, GGT) examination and liver and spleen spiral computed tomography(CT) were performed at starting and 24 week end. To analyze the safty of seal oilω3-PUFA, patient’s symptom,sign ,blood routine,urine routine,ECG,BUN, Cr,uric acid, bilirubin, etc were recorded at starting and at the end of 24th week.Results:1.Comparability between two groups patient :two groups patient basic data and liver-to-spleen CT attenuation ratio had no significantly difference.2.Biochemical changes: The level of serum TG, ALT and GGT of the seal oilω3-PUFA group had significantly decrease compared with placebo group( t=2.592, 2.394, 3.065;P<0.05). The levels of TC,AST,LDL and HDL compared with placebo group had no marked change after treatment( t=1.669,0.792,1.527,-1.174;P>0.05).3.Liver-to-spleen CT attenuation ratio improvement: liver-to-spleen attenuation ratio was significantly improved after 24 weeks treatment,and in comparison with placebo group, the difference was significantly ( P<0.05). Conclusion:1.ω3-PUFA,regulate though cytokines of Adiponectin, CYP2E1 , to relieve liver steatosis , thereby achieve therapeutical effect on Non-alcoholic liver desease.2.Seal oilω3-PUFA has a positive role in improving fatty infiltration for Non-alcoholic fatty liver desease, moreover, seal oil has energetic effect on decreasing serum TG level and protecting liver function.

Related Dissertations

  1. Study of Correlation between Serum Adiponectin Level and Arteriosteogenesis in Patients with Osteoporosis,R580
  2. Effects of Telmisartan on hs-CRP and HMW-adiponectinin Patients with Essential Hypertension,R544.1
  3. The Relationship of Serum Adiponectin、Nitric Oxide Synthase and Carotid Atherosclerosis in Patients with Acute Cerebral Infarction,R743.33
  4. Adiponectin gene signal peptide region prokaryotic expression and ELISA detection method,R392.1
  5. Adiponectin , leptin and type 2 diabetic retinopathy correlation of,R774.1
  6. Osthole Improves Insulin Resistance and Its Possible Mechanisms in Fatty Liver Rats,R285.5
  7. 1. Improvement of tmTNF-α in Insulin Resistance of Adipocytes and Its Underlying Mechanism. 2. Construction of Conserved Sequence Deleted TNF-α Mutant and the Trimerization of Remodeled TNFRBP.,R587.1
  8. The Preliminary Study of Adiponectin Protects Against Anthracycline-induced Cardiotoxicity,R96
  9. The Changes and Influential Factors of Adiponectin、Apelin and Visfatin in Coronary Heart Disease Patients Accompanied with Abnormal Glucose Metabolism,R587.1
  10. Hyperglycemia in patients with metabolic syndrome and changes in coagulation and fibrinolysis system mechanism of rosiglitazone,R589
  11. Atherosclerosis rat model of ADP and inflammatory factor expression and traditional Chinese medicine its control mechanism,R285
  12. Study on the Relationship Between Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome and the Polymorphisms of Adiponectin Gene,R575.5
  13. Epidemiology of Non-alcoholic Fatty Liver Disease and the Impact of Polymorphism of Adiponectin Gene on the Disease: A Study of 4 Years Follow-up,R575.5
  14. The Reference Values of Adiponectin and Resistin in Chinese Adults Living in Changsha City and the Differences in Gender,R446.11
  15. Study on Effects and Mechanism of Saponins of Sea Cucumber on Lipid Metabolism,R285
  16. Investigation of Relationship between Adiponectin and Insulin Resistance in Women with Polycystic Ovary Syndrome,R711.75
  17. Expression of Adioponectin Receptor 2 in Abdominal Subcutaneous Adipose Tissue and Placental Tissue of Patients with Preeclampsia,R714.245
  18. The Relationship of Adiponectin and Cardiac and Cerebral Angiopathy in the Patients with Type 2 Diabetes,R587.1
  19. The Study of Serum Adiponection and Clinical Effect of Granular Particles Baogan Cellulite on Patients with NAFLD of Hepatic Stagnation and Spleen Deficiency Type,R259
  20. The Influence of Leptin and Adiponectin on the Women with Gestational Diabetes Mellitus and the Fetuses,R714.25

CLC: > Medicine, health > Internal Medicine > Digestive and abdominal diseases > Liver and gall bladder disease > Liver metabolic disorders
© 2012 www.DissertationTopic.Net  Mobile